- Trials with a EudraCT protocol (249)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
249 result(s) found for: Emtricitabine.
Displaying page 1 of 13.
EudraCT Number: 2015-000304-26 | Sponsor Protocol Number: GS-US-162-0112 | Start Date*: 2015-01-29 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa with Continued Access to Emtricitabine. | |||||||||||||
Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002205-22 | Sponsor Protocol Number: SSAT047 | Start Date*: 2012-10-02 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicit... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001142-18 | Sponsor Protocol Number: GS-EMC-001 | Start Date*: 2012-08-27 |
Sponsor Name:Erasmus MC | ||
Full Title: Efficacy and pharmacokinetics of a switch from a regimen consisting of emtricitabine, nevirapine and tenofovir to rilpivirine, emtricitabine and tenofovir in virologically suppressed HIV-1 infected... | ||
Medical condition: HIV AIDS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001867-94 | Sponsor Protocol Number: 20-070 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:CHU CAEN Normandie | |||||||||||||
Full Title: Effet du tenofovir/emtricitabine en cure courte sur la clairance virale chez des patients infectés par le SARS-CoV2 (COVID-19) non hospitalisés | |||||||||||||
Medical condition: patients atteints d’une infection SARS-CoV2 non hospitalisés | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000436-62 | Sponsor Protocol Number: GS-US-380-4547 | Start Date*: 2021-02-12 |
Sponsor Name:Gilead Sciences, Inc | ||
Full Title: A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability and Food Effect of a Pediatric Tablet for Oral Suspension of Bictegravir/Emtricitabine/Tenofovir Alafenamide and the... | ||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-003309-79 | Sponsor Protocol Number: MK-8591-024 | Start Date*: 2021-04-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender... | |||||||||||||
Medical condition: HIV Preexposure prophylaxis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000666-37 | Sponsor Protocol Number: 05-IAT-0110 | Start Date*: 2006-06-05 |
Sponsor Name:IATEC B.V. | ||
Full Title: A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Ten... | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004714-40 | Sponsor Protocol Number: GS-US-203-0101 | Start Date*: 2007-09-17 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Randomized, Double Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021785-30 | Sponsor Protocol Number: A4001095 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Prematurely Ended) NL (Completed) PT (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001339-19 | Sponsor Protocol Number: GS-US-311-1269 | Start Date*: 2015-07-28 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing... | |||||||||||||
Medical condition: human immunodeficiency virus-1 (HIV-1) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000308-17 | Sponsor Protocol Number: GS-US-380-4030 | Start Date*: 2017-07-05 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir D... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005927-19 | Sponsor Protocol Number: GESIDA11920 | Start Date*: 2022-05-17 | |||||||||||
Sponsor Name:Fundación SEIMC-GESIDA | |||||||||||||
Full Title: Phase IV, randomized, multicenter, double-blind clinical trial designed to evaluate the safety and convenience of switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir alafe... | |||||||||||||
Medical condition: Human immunodeficiency virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000358-26 | Sponsor Protocol Number: BETAF-RED | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer | |||||||||||||
Full Title: Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults. | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004015-36 | Sponsor Protocol Number: IN-IT-236-1320 | Start Date*: 2015-02-16 |
Sponsor Name:AZIENDA OSPEDALIERA SAN PAOLO | ||
Full Title: Role of a switch strategy to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (QUAD) on HIV reservoir and immune activation. | ||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005672-33 | Sponsor Protocol Number: PR-0095_01 | Start Date*: 2006-07-26 |
Sponsor Name:IATEC B.V. | ||
Full Title: A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens ve... | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Ongoing) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003428-61 | Sponsor Protocol Number: GS-US-380-4449 | Start Date*: 2018-04-06 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001464-36 | Sponsor Protocol Number: GS-US-174-0121 | Start Date*: 2008-12-12 | |||||||||||
Sponsor Name:Gilead Science Incorporated | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Teno... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) HU (Completed) ES (Completed) AT (Completed) GR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000587-23 | Sponsor Protocol Number: MK-8591A-018 | Start Date*: 2020-01-13 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bicte... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) ES (Ongoing) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016758-42 | Sponsor Protocol Number: GS-US-236-0103 | Start Date*: 2010-06-28 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) FR (Completed) PT (Completed) BE (Completed) NL (Completed) AT (Completed) ES (Prematurely Ended) DK (Completed) IT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004038-33 | Sponsor Protocol Number: INMI/001/11 | Start Date*: 2011-11-03 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | |||||||||||||
Full Title: Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days ve... | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
